Aspen Neuroscience, Inc. Form S-1 — Oct 9, 2026
Aspen Neuroscience filed its S-1 for an IPO on Nasdaq under the symbol ASPE, led by Leerink Partners and UBS Investment Bank. The company is a clinical-stage biotech developing autologous iPSC-derived cell therapies for Parkinson's disease, with lead candidate sasineprocel in a Phase 1/2a ASPIRO trial where 15 patients have been dosed. The IPO price range and share count are not yet set, and the underwriters hold a 30-day option for additional shares. Proceeds are earmarked to fund the ongoing ASPIRO trial, initiate a Phase 3 trial in sporadic and genetic Parkinson's, and advance a preclinical microglia program.
Key figures
- Total Debt
- 22540000
- Total Assets
- 110275000
- Cash Position
- 72377000
- Shares Outstanding
- 188558695
- Rd h1 2026
- $28.454 million
- Net loss fy2024
- $48.6 million
- Net loss fy2025
- $62.1 million
- Working capital
- $58.243 million
- Net loss h1 2025
- $31.8 million
- Accumulated deficit
- $264.9 million as of June 30, 2026
- Patients dosed aspiro
- 15
- Preferred conversion shares
- 177593856
- Capital raised since inception
- ~$347 million
- Treatment emergent adverse events
- 72
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.